Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Biotech
Struggling Relmada pays $3M for Tourette’s asset from Asarina
After sharing plans to shutter last summer, Asarina Pharma has managed to sell off its Tourette syndrome candidate to Relmada Therapeutics.
Gabrielle Masson
Feb 7, 2025 11:00am
J&J vet jumps to Affinia—Chutes & Ladders
Feb 7, 2025 8:30am
Sponsored
Carl Sailer on AI, market trends, and strategic planning in biotech
Oct 28, 2024 8:00pm
BMS backs out of Dupixent fight, axing asset despite phase 3 win
Feb 7, 2025 6:26am
Sponsored
Guidehouse’s Karla Anderson shares top tips for successful biotech commercialization
Oct 28, 2024 8:00am
Acelyrin to be absorbed into Alumis in all-stock merger
Feb 7, 2025 5:35am